A Phase 2/3 interventional study of Ublituximab and Placebo in Relapsing Multiple Sclerosis, sponsored by TG Therapeutics, Inc.. Recruiting at 6 sites in 3 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by TG Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ublituximab in Multiple Sclerosis — 5 open to participants now, 7 under way, 4 of them phase 3. ublituximab · Multiple Sclerosis.
Among the 10 studies testing ublituximab in Multiple Sclerosis, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is the only one in phase 2/3, and was the 7th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →5 of the 10 studies testing ublituximab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in Bosnia and Herzegovina, Georgia, North Macedonia and 3 more countries
Ages 18–65
Johns Hopkins University · Sites in United States
Ages 18–65
Northwestern University · Sites in United States
Ages 18–70
TG Therapeutics, Inc. · Sites in United States, Poland
Ages 18–65
By country, each count listing its studies:
ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 6 · Phase 4 2
First in 2016; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 355 across the 10 interventional studies. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 3 most frequent:
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
12 studies in Multiple Sclerosis by TG Therapeutics, Inc.: 6 open now, 9 under way, 4 of them phase 3. Of 3 finished, 3 (100%) have results posted.
Among the 12 studies in Multiple Sclerosis by TG Therapeutics, Inc., this one is one of 2 that started in 2026, is the only one in phase 2/3, and was the 11th registered.
TG Therapeutics, Inc.’s Multiple Sclerosis studies by the year they started, since 2016.
2 of the studies testing ublituximab in Multiple Sclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT07503873TG Therapeutics, Inc.A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing ublituximab in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among TG Therapeutics, Inc.’s 12 in Multiple Sclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (\<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to less than or equal to (≤)40 kg with RMS (Part A) and to evaluate the non-inferiority of ublituximab compared with fingolimod in pediatric RMS participants with body weight ≥ 25 kg (Part B). The study will further evaluate long-term safety and efficacy of ublituximab in RMS in pediatric participants during its extension period (Part C).
Inclusion Criteria for Part A and Part B:
Inclusion Criteria for Part C:
1. Participants must have completed Part A (Week 24 visit) or Part B (Week 96 visit) to be eligible for Part C.
Exclusion Criteria for Part A and B:
Prior treatments:
Additional Exclusion Criteria for Part B Only (Relevant to Fingolimod Treatment):
Exclusion Criteria for Part C:
1. If the absolute lymphocyte count (ALC) is outside the specified range the participant will not be eligible to receive ublituximab in Part C.
Note: Other protocol-specified inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
New Regimen
Drug: Ublituximab
New Regimen
Drug: Ublituximab
Drug: Placebo
Drug: Fingolimod
Drug: Placebo
Drug: Ublituximab
Administered as an intravenous (IV) infusion.
Also known as: TG-1101, BRIUMVI
Oral capsule.
IV infusion.
Oral capsule.
Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab
Time frame: Predose and multiple timepoints up to Week 24
Part A: Maximum Observed Concentration (Cmax) of Ublituximab
Time frame: Day 1 and Day 15
Part A: Participant B Cell Counts
Time frame: Up to Week 24
Part B: Annualized Relapse Rate (ARR)
Time frame: Up to 96 weeks
Part C: Annualized Relapse Rate (ARR)
Time frame: Up to 168 weeks
Part A, B and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks; Part C: Up to 168 weeks
Part A, B and C: Number of Participants With Change in Columbia-Suicide Severity Rating Scale (C-SSRS )
Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks; Part C: Up to 168 weeks
Part A: Serum Concentrations of Ublituximab
Time frame: Up to Week 24
Part A and B: Percentage of Participants with Treatment-emergent Anti-drug Antibodies (ADAs) to Ublituximab
Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks
Part A and B: Number of Gadolinium Enhancing (Gd-enhancing) T1 Lesions per Magnetic Resonance Imaging (MRI) Scan
Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks
Part A and B: Number of New and/or enlarging T2 Hyperintense Lesions (NELs) per MRI Scan
Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks
Past A: Annualized Relapse Rate
Time frame: Up to Week 24
Part A and C: Change From Baseline in Expanded Disability Status Scale (EDSS) Score
Time frame: Part A: Baseline, up to Week 24; Part C: Baseline, up to 168 weeks
Part B: Pharmacokinetics (PK) Serum Concentration of Ublituximab
Time frame: Up to Week 96
Part B: Percentage of Participants with CD19+ B cell counts ≤10 cells/uL
Time frame: Up to 96 weeks
Part B: Annualized Relapse Rate ARR
Time frame: Up to Week 96
Part C: Time to Confirmed Disability Progression (CDP)
Time frame: Up to Week 24
Part C: Time to Confirmed Disability Improvement (CDI)
Time frame: Up to Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jan 2030, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ublituximab · Fingolimod